1. Left ventricular hypertrophy as a predictor of cardiovascular outcomes after transcatheter aortic valve replacement
- Author
-
Nobuyasu Ito, Kan Zen, Motoyoshi Takahara, Ryotaro Tani, Shunsuke Nakamura, Tomotaka Fujimoto, Kazuaki Takamatsu, Masaki Yashige, Yoshito Kadoya, Michiyo Yamano, Tetsuhiro Yamano, Takeshi Nakamura, Hitoshi Yaku, and Satoaki Matoba
- Subjects
Transcatheter aortic valve replacement ,Aortic stenosis ,Left ventricular hypertrophy ,Cardiac sympathetic nerve function ,123I‐Metaiodobenzylguanidine scintigraphy ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims This study aimed to clarify the relationship between cardiovascular prognosis and left ventricular hypertrophy (LVH) in patients with severe aortic stenosis who underwent transcatheter aortic valve replacement (TAVR) and to investigate the relationship between cardiac sympathetic nerve (CSN) function and these factors using 123I‐metaiodobenzylguanidine scintigraphy. Methods and results In this single‐centre, retrospective observational study, 349 patients who underwent TAVR at our institution between July 2017 and May 2020 were divided into two groups: those with severe LVH pre‐operatively [severe LVH (+) group] and those without LVH pre‐operatively [severe LVH (−) group]. The rates of freedom from cardiovascular events (cardiovascular death and heart failure hospitalization) were compared. The relationship between changes in left ventricular mass index (LVMi) and changes in delay heart–mediastinum ratio (H/M) from before TAVR to 6 months after TAVR was also investigated. The event‐free rate was significantly lower in the severe LVH (+) group (87.1% vs. 96.0%, log‐rank P = 0.021). The severe LVH (+) group exhibited a significantly lower delay H/M value, scored by 123I‐metaiodobenzylguanidine scintigraphy, than the severe LVH (−) group (2.33 [1.92–2.67] vs. 2.67 [2.17–3.68], respectively, P
- Published
- 2023
- Full Text
- View/download PDF